Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Pennsylvania: - UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- Carlisle Regional Cancer Center — Carlisle, Pennsylvania
- Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Chambersburg Hospital — Chambersburg, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…
Sponsor: NRG Oncology
NCT ID: NCT04134260
Sites in Pennsylvania: - UPMC Altoona — Altoona, Pennsylvania
- UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- Crozer-Keystone Regional Cancer Center at Broomall — Broomall, Pennsylvania
- Carlisle Regional Cancer Center — Carlisle, Pennsylvania
- Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Pennsylvania: - Saint Vincent Hospital — Erie, Pennsylvania
- Jefferson Hospital — Jefferson Hills, Pennsylvania
- Forbes Hospital — Monroeville, Pennsylvania
- Allegheny Valley Hospital — Natrona Heights, Pennsylvania
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in Pennsylvania: - Research Site — Bala-Cynwyd, Pennsylvania
- Research Site — Philadelphia, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
- Research Site — York, Pennsylvania
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Pennsylvania: - The Centers for Advanced Urology, LLP d/b/a Keystone Urology Specialists — Lancaster, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Pennsylvania: - MidLantic Urology — Bala-Cynwyd, Pennsylvania
- Keystone Urology Specialists — Lancaster, Pennsylvania
- Penn Medicine Abramson Cancer Center — Philadelphia, Pennsylvania
- UPMC Cancer Centers — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
Sponsor: Amgen
NCT ID: NCT06691984
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Pennsylvania: - Lehigh Valley Hospital — Allentown, Pennsylvania
- MidLantic Urology — Bala-Cynwyd, Pennsylvania
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06970847
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
- UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
- Saint Vincent Hospital — Erie, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Pennsylvania: - Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- WellSpan York Cancer Center — York, Pennsylvania
Phase 2 Recruiting Industry
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Sponsor: Dendreon
NCT ID: NCT06134232
Sites in Pennsylvania: - MidLantic Urology — Bala-Cynwyd, Pennsylvania
- Keystone Urology Specialists — Lancaster, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Pennsylvania: - University of Pittsburgh Medical Center, Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Pennsylvania: - Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Pennsylvania: - Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant pr…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06457919
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back afte…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07111507
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06863272
Sites in Pennsylvania: - UPMC Hillman Cancer Center ( Site 0014) — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk lo…
Sponsor: Rana McKay, MD
NCT ID: NCT05498272
Sites in Pennsylvania: - Penn Medicine Abramson Cancer Center — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
Phase 1: The objective of the Phase 1 part of the clinical trial is to verify safety and tolerability (dose-limiting toxicity \[DLT\], maximum tolerated dose \[MTD\]) of a single 3.7 Giga-Becquerel (GBq) dose with the potential for one dos…
Sponsor: FutureChem
NCT ID: NCT05458544
Sites in Pennsylvania: - Pennsylvania Cancer Specialists & Research Institute (Formerly Gettysburg Cancer Center) — Gettysburg, Pennsylvania
Phase 2 Recruiting Academic/Other
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Sponsor: Abramson Cancer Center at Penn Medicine
NCT ID: NCT06591819
Sites in Pennsylvania: - University of Pennsylvania — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended…
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06600698
Sites in Pennsylvania: - Penn State Cancer Institute — Hershey, Pennsylvania
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Pennsylvania: - Exelixis Clinical Site #104 — Hershey, Pennsylvania
- Exelixis Clinical Site #98 — Philadelphia, Pennsylvania
- Exelixis Clinical Site #32 — Pittsburgh, Pennsylvania
- Exelixis Clinical Site #24 — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania